Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14868624 | 0.75 | TSHR (0.34) | ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL14868749 | 0.73 | PRMT6 (0.49) | METAP2KDM4CNPC1RAB9AALDH1A1 | |
| SCHEMBL24433706 | 0.71 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL7666344 | 0.71 | POLB (0.60) | RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL17198946 | 0.70 | LMNA (0.46) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL8128594 | 0.70 | POLB (0.58) | RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL14868622 | 0.70 | — | — | |
| SCHEMBL13024413 | 0.69 | PDE10A (0.44) | METAP2KDM4CPDE10AMAOARAB9A | |
| SCHEMBL17198839 | 0.69 | NPC1 (0.47) | NPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL14868719 | 0.69 | KMT2A (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063780-A1 | Pharmaceutical preparations for treatment of type II diabetes and methods for treatment of type II diabetes | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063780-A1 | Pharmaceutical preparations for treatment of type II diabetes and methods for treatment of type II diabetes | SLC5A2, SLC5A1, IAPP | METAP2 604/4885KDM4C 4585/4885PDE10A 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.